Right before Christmas last year, the Department of Justice announced an ominous settlement: United Therapeutics, a manufacturer of pulmonary arterial hypertension drugs, agreed to pay more than $200 million to settle allegations it violated the Anti-Kickback Statute . United Therapeutics' alleged kickback was supporting - and purportedly benefiting from - a Patient Assistance Program charitable foundation that helped patients pay expensive co-pays for United Therapeutics' drugs.